Volume 12, Issue 2 (March & April 2021)
BCN 2021, 12(2): 233-242 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yavari F, Oliazadeh P, Radfar M, Foroughipour M, Nikkhah K, Heidari Bakavoli A et al . Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis. BCN 2021; 12 (2) :233-242
URL: http://bcn.iums.ac.ir/article-1-1412-en.html
URL: http://bcn.iums.ac.ir/article-1-1412-en.html
Fatemeh Yavari1 
, Pardis Oliazadeh2 , Meisam Radfar3 , Mohsen Foroughipour1 , Karim Nikkhah1 , Alireza Heidari Bakavoli4 , Morteza Saeidi * 1
, Pardis Oliazadeh2 , Meisam Radfar3 , Mohsen Foroughipour1 , Karim Nikkhah1 , Alireza Heidari Bakavoli4 , Morteza Saeidi * 1
1- Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
2- School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Department of Biotechnology and Plant Breeding, Gorgan University of Agricultural Sciences and Natural Recourses, Golestan, Iran.
4- Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2- School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Department of Biotechnology and Plant Breeding, Gorgan University of Agricultural Sciences and Natural Recourses, Golestan, Iran.
4- Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS.
Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of Dadolinium (Gd)-enhanced lesions, enlarged T2 lesions, and relapses over 12 months were considered as endpoints and compared to baseline. Liver biochemical evaluations and lymphocyte count were done at baseline and in months 3, 6, and 12 of the study. Patients were also monitored for possible cardiovascular events within the first 24 h and other side effects routinely.
Results: Among the patients who completed the trial, the number of Gd-enhanced and enlarged T2 lesions over 12 months significantly decreased (P=0.03 and P<0.001, respectively). The proportion of relapse-free patients was higher compared to the onset of fingolimod administration. There were no significant alterations in the Expanded Disability Status Scale (EDSS) scores. A slight, transient increase was recorded in liver enzymes among the participants. Lymphocyte count reduced by 61% at month 1 and displayed a gradual increase until month 12. No bradycardia and macular edema were recorded.
Conclusion: These findings indicate an effective first-line fingolimod therapy for the first time in Iranian patients with RRMS. The decrease in the number of new attacks and the amelioration of MRI lesions were the benefits of fingolimod therapy, suggesting that it is preferred to other medicines to treat RRMS in Iran.
Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of Dadolinium (Gd)-enhanced lesions, enlarged T2 lesions, and relapses over 12 months were considered as endpoints and compared to baseline. Liver biochemical evaluations and lymphocyte count were done at baseline and in months 3, 6, and 12 of the study. Patients were also monitored for possible cardiovascular events within the first 24 h and other side effects routinely.
Results: Among the patients who completed the trial, the number of Gd-enhanced and enlarged T2 lesions over 12 months significantly decreased (P=0.03 and P<0.001, respectively). The proportion of relapse-free patients was higher compared to the onset of fingolimod administration. There were no significant alterations in the Expanded Disability Status Scale (EDSS) scores. A slight, transient increase was recorded in liver enzymes among the participants. Lymphocyte count reduced by 61% at month 1 and displayed a gradual increase until month 12. No bradycardia and macular edema were recorded.
Conclusion: These findings indicate an effective first-line fingolimod therapy for the first time in Iranian patients with RRMS. The decrease in the number of new attacks and the amelioration of MRI lesions were the benefits of fingolimod therapy, suggesting that it is preferred to other medicines to treat RRMS in Iran.
Keywords: Multiple sclerosis, Fingolimod, Expanded Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), Cardiovascular events, Therapy
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2020/01/23 | Accepted: 2020/12/1 | Published: 2021/03/1
Received: 2020/01/23 | Accepted: 2020/12/1 | Published: 2021/03/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
